Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer
Based on DESTINY-Gastric02 which showed AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated clinically meaningful efficacy and DESTINY-Gastric01 which showed improved overall survival compared to chemotherapy.AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug